Sugi Predict

Sugi Predict / Compounds / SCHEMBL7066155

SCHEMBL7066155

SCHEMBL7066155

COCC(C)NC1=NSc2cnccc2N1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.32
▸ CDC7 O00311 1/20 0.31
▸ ROCK2 O75116 1/20 0.31
▸ MAP4K4 O95819 1/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ PRKACA P17612 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ HIPK2 Q9H2X6 1/20 0.31
▸ CLK4 Q9HAZ1 1/20 0.31
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ JAK2 O60674 2/20 0.31
▸ JAK3 P52333 2/20 0.31
▸ NAMPT P43490 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067970 0.85 GAA (0.36) GAAMAPTIDO1L3MBTL1
SCHEMBL8717631 0.81 GAA (0.34) GAAMAPTIDO1L3MBTL1
SCHEMBL8584147 0.79 HPGD (0.36) HCAR3GAAMAPTCDC7ROCK2
SCHEMBL8580846 0.79 NOX1 (0.34) HCAR3NAMPT
SCHEMBL8720440 0.79 GAA (0.35) GAAMAPTIDO1L3MBTL1
SCHEMBL7066158 0.78 LATS1 (0.39) GAAMAPTIDO1L3MBTL1
SCHEMBL8722401 0.77 GAA (0.41) GAAMAPTIDO1L3MBTL1
SCHEMBL8720177 0.76 GAA (0.38) GAAMAPTIDO1L3MBTL1
SCHEMBL7069716 0.76 KDM4C (0.43) GAAMAPTIDO1L3MBTL1ROCK2
SCHEMBL8717871 0.76 GAA (0.35) GAAMAPTIDO1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 — — WO claimed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO claimed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO claimed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 — — WO claimed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 — — WO claimed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 — — EP claimed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 — — WO claimed
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 — — WO disclosed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO disclosed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 — — WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 — — WO disclosed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 — — EP disclosed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 — — WO disclosed